Actualités

(Bloomberg) -- Apple Inc. and the US Justice Department are in early discussions about settling a 2024 lawsuit that alleges the iPhone maker violated antitrust laws. Most Read from BloombergFCC Near Rulings Against Disney Over ‘The View,’ TV LicensesChip Stocks Poised for Bear Market in AI Unwind: Markets WrapGoogle Gemini Launch Delayed as Tech Falls Short of Internal GoalsChina’s Moonshot Unveils AI Model That Narrows Gap With US FirmsThailand Scraps Plan to End Visa-Free Entry for Indian Tour

NEW YORK, July 17 (Reuters) - A New York state judge dismissed a lawsuit by a former JPMorgan Chase banker who in graphic terms said his former supervisor coerced him into sex and demanded his

MSD has outpaced rivals to market the first PCSK9 inhibitor in pill form for patients with high cholesterol.

3M stock has more than doubled over the past three years, while current checks suggest the shares trade below an intrinsic value estimate based on a Discounted Cash Flow (DCF) approach and also screen as undervalued on traditional earnings multiples. At the same time, a mixed broader valuation score and fresh legal action over PFAS chemicals mean the gap between price and estimated value is not a straightforward story. 3M has delivered a 103.6% return over the last three years, which puts...

There's a reason Costco will pretty much let you return any item at any time without a hassle. Costco has built its reputation on offering high-quality products at competitive prices, backed by strict supplier standards and careful product selection. The company knows its products have been ...

The daily medication is expected to be list-priced at $10.50 per pill. Here's what to know about Merck's new cholesterol drug Lipfendra.

Lipfendra, to be taken once a day, is designed to help lower cholesterol levels beyond what statins alone can achieve.

In April 2026, Intuitive Surgical voluntarily initiated an ongoing Class II worldwide recall of certain da Vinci surgical system components after discovering an E-brake retainer pin issue that could impede emergency braking or cause uncontrolled column motion, with 454 affected units identified by specific serial numbers. This safety action, alongside growing attention on Intuitive’s AI-enabled da Vinci 5 rollout and competitive pressures in robotic surgery, raises fresh questions about how...

European cloud and infrastructure groups have challenged Broadcom over recent VMware licensing changes following the acquisition. Trade association CISPE and others have asked EU antitrust regulators to review and suspend certain Broadcom practices tied to VMware contracts. The European Commission has opened an antitrust review that centers on access, pricing, and conditions for VMware software in the region. Broadcom (NasdaqGS:AVGO) is coming under closer regulatory scrutiny in Europe at a...

Apple stock has gained 121.0% over the past 5 years, yet its current valuation checks are split, with a Discounted Cash Flow (DCF) intrinsic value estimate suggesting the shares trade at a premium while earnings based multiples still screen as relatively supportive. That tension leaves investors weighing a strong long term share price record against signals that today’s price may already reflect a lot of optimism. Apple’s 121.0% return over 5 years highlights how strongly the stock has...

OpenAI’s struggles could cause the AI bubble to burst, bringing down with it much more than the company’s hardware division.

OpenAI says it sees no evidence supporting Apple's lawsuit over alleged trade-secret theft.

OpenAI plans a screen-free AI home device while Apple seeks an injunction that could delay its rollout.

OpenAI still plans a year-end device reveal, but Apple's lawsuit, ecosystem strength and rising component costs may complicate its hardware push.

Pfizer Inc. (NYSE:PFE) is one of the 8 Worst Blue Chip Stocks to Buy Now. On July 10, 2026, Pfizer Inc. (NYSE:PFE) and Astellas Pharma (ALPMY) announced that the U.S. Food and Drug Administration approved PADCEV, a Nectin-4 directed antibody-drug conjugate, plus the PD-1 inhibitor Keytruda or Keytruda QLEX as neoadjuvant and adjuvant treatment for […]

July 15 () - Shares of Celcuity fell about 8% in premarket trading on Wednesday, as the delayed commercial launch ‌of its newly approved breast cancer drug and treatment-tolerability ‌concerns overshadowed the company's first U. Food and Drug Administration on ​Tuesday approved gedatolisib, branded as Revtorpyk, for certain patients with advanced breast cancer whose tumors do not carry a PIK3CA mutation.

Just one day after glowing reviews, a surprise revenue warning sent the stock into a tailspin and brought lawyers to the door.

Still, shares fell by nearly 20% after the company revealed a delay in the coming launch of Revtorpyk. Details in the drug’s prescribing information surprised some analysts, too.

Alphabet unit Google on Wednesday urged Europe's top court to dismiss EU antitrust regulators' appeal ‌against a lower court ruling that scrapped a €1.49 billion ($1.7 billion) fine, saying ‌the regulators' arguments were flawed. The dispute reached the Court of Justice of the European Union ​after regulators appealed a 2024 General Court ruling that annulled the fine imposed on Google in 2019. The lower court cited errors in the European Commission's assessment of the case.

The primary reason for the 12-state lawsuit is that a Paramount-WBD combination would curb entertainment content and distribution, putting the TV/movie marketplace into fewer hands. What's the fallout?

FDA grants full approval to Eli Lilly's selpercatinib (Retevmo) for a wider group of adult and pediatric patients with RET fusion solid tumors. The decision shifts selpercatinib from accelerated to traditional approval and broadens its labeled use across multiple tumor types. The update reinforces Eli Lilly's (NYSE:LLY) position in oncology and opens new commercial and clinical avenues for the drug. Eli Lilly, known for its oncology and biopharma portfolio, now has a fully approved RET...

The product is expected to be OpenAI’s first physical AI device and a crucial milestone as the company moves forward with its IPO plans.

Boston Scientific recently initiated several voluntary Class II recalls of its CRE and CRE Pro Wireguided endoscopy devices worldwide due to potential sterile breaches in packaging, affecting tens of thousands of units across multiple size ranges. The recalls underscore the operational and regulatory risks inherent in Boston Scientific’s expanding minimally invasive device portfolio, especially as it integrates recent acquisitions and scales global distribution. We’ll now examine how these...

Pfizer, trading as NYSE:PFE, received FDA approval for a platinum-free Padcev-Keytruda regimen in muscle-invasive bladder cancer. The regimen is approved as both neoadjuvant and adjuvant therapy for adult patients, regardless of cisplatin eligibility. This decision expands use of the combination across a broader bladder cancer population and introduces a new treatment option. For investors watching Pfizer at a share price of $24.25, this approval adds a fresh development to the oncology...

The U.S. Department of Justice has expanded an antitrust investigation to include UnitedHealth Group's Claritev unit. The Claritev review is part of broader DOJ scrutiny of healthcare industry practices and market competition. This development adds a fresh layer of regulatory attention for UnitedHealth Group (NYSE:UNH) beyond routine oversight. UnitedHealth Group, one of the largest managed care and healthcare services companies in the U.S., spans insurance, care delivery, and data-driven...

OpenAI has issued another statement on the lawsuit, this time suggesting it lacks merit.

Apple seeks damages and other legal remedies that could slow OpenAI's device development and hiring.

OpenAI says it takes Apple’s complaint seriously but questions whether the allegations have any merit.

Gedatolisib, in-licensed from Pfizer in 2021, is Celcuity’s sole late-stage asset.

There’s no sugarcoating it; getting laid off is awful. But if you've been following the news, it feels like tech workers are being laid off left and right. Here’s what one Reddit user, who was recently laid off from an account executive role at a tech company, had to say on the r/Layoffs subreddit: ...